Kedudukan dalam Saham
#15445
BioAge Labs, Inc., a clinical-stage biopharmaceutical company, develops... BioAge Labs, Inc., a clinical-stage biopharmaceutical company, develops therapeutic product candidates for metabolic diseases. The company’s technology platform and differentiated human datasets that allows users to identify targets based on insights into molecular changes that drive aging. Its lead product candidate includes BGE-102, an orally available brain-penetrant small-molecule NLRP3 inhibitor which is in Phase 1 clinical trail for the treatment of atherosclerotic cardiovascular disease, as well as for the treatment of diabetic macular edema and geographic atrophy; and develops APJ agonists for obesity, including programs targeting both oral and parenteral administration. The company has collaboration agreement with Novartis Pharma AG to identify and validate novel therapeutic drug targets by investigating the biological mechanisms that drive diseases related to aging and mediate. BioAge Labs, Inc. was incorporated in 2015 and is headquartered in Emeryville, California.
Harga Saham
$9.34
Disegerakkan terakhir: 2026-08-31
Perubahan (1 hari)
-3.20%
Perubahan (1 tahun)
89.48%
Perdagangan BioAge Labs Inc. (BIOA)
Harga BIOA dengan permodalan pasaran b
Modal pasaran bagi BioAge Labs Inc.(BIOA)
Modal Pasaran: $351.70M
Sehingga September 2026, BioAge Labs Inc. mempunyai modal pasaran sebanyak $351.70M. Ini menjadikan BioAge Labs Inc. syarikat ke-15445th paling bernilai di dunia mengikut data kami. Kapitalisasi pasaran ialah nilai keseluruhan saham syarikat tersenarai yang berada dalam edaran dan lazimnya digunakan untuk menilai nilai syarikat tersebut.
Sejarah modal pasaran BioAge Labs Inc. dari 2024 hingga 2026
BIOA berbanding dengan 5 teratas yang paling popular stocks
| Harga BIOA |
|
Aset B |
Pasaran B |
Hasilnya |
|
|
|
|
$5.327T
|
+1,514,486.04%
|
|
|
|
|
$4.645T
|
+1,320,591.64%
|
|
|
|
|
$4.070T
|
+1,157,209.34%
|
|
|
|
|
$3.785T
|
+1,075,981.05%
|
|
|
|
|
$2.790T
|
+793,224.00%
|
